What is BridgeBio Pharma's operating lease liabilities?

BridgeBio Pharma (BBIO) reported operating lease liabilities of -$1.85M in Q1 2026.

How has BridgeBio Pharma's operating lease liabilities changed year-over-year?

BridgeBio Pharma's operating lease liabilities decreased by 26.0% year-over-year, from -$1.47M to -$1.85M.

What is the long-term trend for BridgeBio Pharma's operating lease liabilities?

Over 4 years (2021 to 2025), BridgeBio Pharma's operating lease liabilities has grown at a 1.7% compound annual growth rate (CAGR), from -$6.12M to -$6.55M.

BridgeBio Pharma BBIO Operating lease liabilities

Operating lease liabilities at other companies

Revolution Medicines, Inc.RVMD

——

Roivant SciencesROIV

——

Arrowhead ResearchARWR

——

Axsome TherapeuticsAXSM

——

Medpace Holdings, Inc.MEDP

——

Other financials

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

See full

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BridgeBio Pharma's operating lease liabilities?: BridgeBio Pharma (BBIO) reported operating lease liabilities of -$1.85M in Q1 2026.
How has BridgeBio Pharma's operating lease liabilities changed year-over-year?: BridgeBio Pharma's operating lease liabilities decreased by 26.0% year-over-year, from -$1.47M to -$1.85M.
What is the long-term trend for BridgeBio Pharma's operating lease liabilities?: Over 4 years (2021 to 2025), BridgeBio Pharma's operating lease liabilities has grown at a 1.7% compound annual growth rate (CAGR), from -$6.12M to -$6.55M.